StockData

ABVC BioPharma vs Lexaria Bioscience

ABVC and LEXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABVC and LEXX compare

Lexaria Bioscience is the larger company, worth 4.1 times as much as ABVC BioPharma ($104M against $25.1M).

Lexaria Bioscience scores higher on the StockData Score (8 against 2 for ABVC BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABVCLEXX
Size and price
Market cap$25.1M$104M
Share price$0.940$4.18
Change, 1 year−66.4%−73.7%
Change, 5 years−97.1%−94.8%
Beta (5Y)1.720.13
Employees19134
StockData Score
Total score28 (better)
Valuation score00
Growth score02 (better)
Performance score00
Health score26 (better)
Dividend score00
Valuation
P/S–534×
P/B2.4× (better)21.9×
FCF yield–−7.2%
Growth
Revenue growth (TTM)–−68.5%
Revenue growth, 5Y average−9.3%17.5% (better)
Profitability
Gross margin–100%
Operating margin–−3973%
Net margin–−3986%
FCF margin–−3849%
Return on equity−82.2% (better)−150%
Return on invested capital−60.6% (better)−602%
Financial health
Debt / equity0.01 (better)0.00
Interest coverage−42.0×–
Current ratio0.0710.60 (better)
Altman Z-score−5.04117.82 (better)
Piotroski F-score5 (better)2
Dividends and buybacks
Buyback yield–−6.3%
Shareholder yield0.00% (better)−6.3%
Ownership
Held by institutions4.1%–
Held by insiders0.49%3.0%
Short interest, % of float–0.90%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.